K2X Technology & Life Science, Inc.

Equities

KBPH

US5015722003

Financial & Commodity Market Operators

Market Closed - OTC Markets Other stock markets 01:00:56 23/08/2022 am IST			5-day change	1st Jan Change
1 ^USD	-45.65%		-.--%	-.--%

2023	FluidAI Medical announced that it has received CAD 15 million in funding from a group of investors	CI
2023	Infinidome Ltd. announced that it has received $9 million in funding from Hanwha Aerospace Co., Ltd., Next Gear Ventures, Honeywell Ventures, VentureIsrael, Kyto Technology and Life Science, Inc., Aston Capital Management and another investor	CI

Kyto Technology and Life Science, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2020

August 04, 2020 at 03:36 pm IST

Kyto Technology and Life Science, Inc. announced earnings results for the first quarter ended June 30, 2020. For the first quarter, the company announced sales was USD 500 compared to USD 3,250 a year ago. Operating loss was USD 38,868 compared to USD 201,598 a year ago. Net loss was USD 38,868 compared to USD 201,598 a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.03 a year ago.

Latest news about K2X Technology & Life Science, Inc.

FluidAI Medical announced that it has received CAD 15 million in funding from a group of investors	10/23/10	CI
Infinidome Ltd. announced that it has received $9 million in funding from Hanwha Aerospace Co., Ltd., Next Gear Ventures, Honeywell Ventures, VentureIsrael, Kyto Technology and Life Science, Inc., Aston Capital Management and another investor	24/23/24	CI
Mrinq Technologies LLP announced that it has received $2.5 million in funding from a group of investors	10/22/10	CI
Kyto Technology and Life Science, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22/22/22	CI
Kyto Technology and Life Science, Inc. announced that it has received $2.620875 million in funding	04/22/04	CI
Rhaeos, Inc. announced that it has received $2.2 million in funding from a group of investors	23/21/23	CI
Kyto Technology and Life Science, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	18/21/18	CI
Kyto Technology and Life Science, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2021	01/21/01	CI
Kyto Technology and Life Science, Inc. announced that it has received $0.21 million in funding	01/21/01	CI
Kyto Technology and Life Science, Inc. announced that it has received $0.3 million in funding	17/21/17	CI
Kyto Technology and Life Science, Inc. announced that it has received $0.135 million in funding	13/21/13	CI
Kyto Technology and Life Science, Inc. announced that it has received $0.703 million in funding	12/21/12	CI
Kyto Technology and Life Science, Inc. Reports Earnings Results for the Full Year Ended March 31, 2021	10/21/10	CI
Kyto Technology and Life Science, Inc. Auditor Raises 'Going Concern' Doubt	10/21/10	CI
Single Pass Inc. announced that it has received funding from Kyto Technology and Life Science, Inc., and another investor	09/21/09	CI
AOA Inc. announced that it has received $2.5 million in funding from a group of investors	28/21/28	CI
Kyto Technology and Life Science, Inc. Announces Resignation of Georges Benarroch from the Board of Directors	12/21/12	CI
AOA Inc. announced that it expects to receive $2.5 million in funding	26/21/26	CI
Kyto Technology and Life Science, Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2020	17/21/17	CI
Kyto Technology and Life Science, Inc. Announces Board Changes	14/21/14	CI
Astrocyte Pharmaceuticals Inc. announced that it has received $7.522677 million in funding from CR Ventures, DeepWork Capital, Trend Investment Group, Kyto Technology and Life Science, Inc. and other investors	10/20/10	CI
Astrocyte Pharmaceuticals Inc. announced that it expects to receive $9.831429 million	20/20/20	CI
Kyto Technology and Life Science, Inc. Reports Earnings Results for the Second Quarter Ended September 30, 2020	16/20/16	CI
Kyto Technology and Life Science, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2020	04/20/04	CI
Kyto Technology and Life Science, Inc. Reports Earnings Results for the Full Year Ended March 31, 2020	01/20/01	CI

Chart K2X Technology & Life Science, Inc.

Duration

Period

Chart K2X Technology & Life Science, Inc.

More charts

Company Profile

Kyto Technology and Life Science, Inc. is an investment company focused on creating an exchange-traded fund (ETF)-like vehicle of diversified and thoroughly vetted start-ups thus defining an entirely new non-correlated asset class. The Companyâs portfolio includes AbFero Pharmaceuticals Inc., Achelios Therapeutics, Inc., Altis Biosystems, AmplifiDX, AOA Inc., Astrocyte Pharmaceuticals Inc. and other.

Sector

Financial & Commodity Market Operators

More about the company

Sector Other Financial & Commodity Market Operators

	1st Jan change	Capi.
K2X TECHNOLOGY & LIFE SCIENCE, INC.	-.--%	16.33M
INTERCONTINENTAL EXCHANGE, INC.	+7.76%	79.38B
LONDON STOCK EXCHANGE PLC	+0.67%	62.88B
HONG KONG EXCHANGES AND CLEARING LIMITED	+10.07%	47.82B
DEUTSCHE BÖRSE AG	-1.05%	37.14B
NASDAQ, INC.	+7.95%	36.18B
B3 S.A. - BRASIL, BOLSA, BALCÃO	-21.51%	12.22B
EURONEXT N.V.	+16.72%	10.35B
MARKETAXESS HOLDINGS INC.	-26.68%	8.14B
TMX GROUP LIMITED	+14.51%	7.48B

Other Financial & Commodity Market Operators